New ulcerative colitis drug put through drug interaction test
NCT ID NCT07665723
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing whether afimkibart, an experimental drug for ulcerative colitis, changes how the body processes common medications like caffeine, warfarin, and omeprazole. About 25 people with moderate to severe active ulcerative colitis will receive afimkibart along with a cocktail of these drugs to measure any interactions. The goal is to gather safety and drug-processing data, not to treat the disease directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Afimkibart (also known as RO7790121, PF-06480605, RVT-3101)
What this could lead to
If successful, this study will show whether afimkibart changes how the body processes other drugs, helping doctors prescribe safer combinations for ulcerative colitis.
What could go wrong
This is a very early, small study (25 people) focused on drug interactions, not on treating the disease itself. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charite Research Organisation GmbH
RECRUITINGBerlin, 10117, Germany
-
Erick H. Alayo Medical Corporation - Gastro SB Clinic
RECRUITINGChula Vista, California, 91910, United States
-
Gastro Health Research
RECRUITINGMiami, Florida, 33176-2416, United States
-
Royal Liverpool University Hospital
RECRUITINGLiverpool, L7 8XP, United Kingdom
-
Royal Victoria Infirmary
RECRUITINGNewcastle upon Tyne, NE1 4LP, United Kingdom
-
University College London Hospitals
RECRUITINGLondon, W1T 7HA, United Kingdom